Roche's Tecentriq: Phase III IMpower110 study at ESMO 2019 - 0 views
-
ramchintamaneni on 18 Oct 19Roche's Tecentriq: Results demonstrated that first-line treatment of patients with advanced non-small cell lung cancer and high programmed cell death ligand-1 expression who used Roche's Tecentriq monotherapy resulted in improved overall survival compared with platinum-based chemotherapies.